On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development
Matthias Evert, Frank Dombrowski, Biao Fan, Silvia Ribback, Xin Chen, Diego F. Calvisi – 23 March 2013
Matthias Evert, Frank Dombrowski, Biao Fan, Silvia Ribback, Xin Chen, Diego F. Calvisi – 23 March 2013
Petia Jeliazkova, Simone Jörs, Jens T. Siveke, Fabian Geisler – 23 March 2013
Yu‐Shu Cheng, Ping‐Yi Lin, Kuo‐Hua Lin, Chih‐Jan Ko, Chia‐Cheng Lin, Yao‐Li Chen – 22 March 2013
Eytan Mor, Eviatar Nesher, Ziv Ben‐Ari, Irit Weissman, Ezra Shaharabani, Sigal Eizner, Evegny Solomonov, Ruth Rahamimov, Marius Braun – 22 March 2013 – Using living donor organs for sequential liver and kidney transplantation (SeqLKT) in patients with primary hyperoxaluria type 1 (PH1) has emerged as a viable approach. Taking both organs from a single donor, however, is rare. There are 8 reported cases of SeqLKT in the literature, and in all but 1 case, children were the recipients. We present our experience with SeqLKT in 2 young adults with PH1.
Humberto E. Bohorquez, Ari J. Cohen, Nigel Girgrah, David S. Bruce, Ian C. Carmody, Shoba Joshi, Trevor W. Reichman, George Therapondos, Andrew L. Mason, George E. Loss – 22 March 2013 – The use of livers from hepatitis B surface antigen–negative (HBsAg−)/hepatitis B core antibody–positive (HBcAb+) donors in liver transplantation (LT) for HBsAg−/HBcAb− recipients is still controversial because of a lack of standard antiviral prophylaxis and long‐term follow‐up. We present our 13‐year experience with the use of HBcAb+ donor livers in HBcAb− recipients.
Ignacio A. Echenique, Michael G. Ison – 22 March 2013 – Advances in surgical techniques, immunosuppressive medications, and robust infectious disease prophylaxis have resulted in liver transplantation becoming the treatment of choice for patients with end‐stage liver disease and unresectable hepatocellular carcinoma. Nonetheless, organ transplantation is not without risk. Unexpected donor‐derived disease transmission is a newly recognized risk that complicates approximately 0.2% of all organ transplants.
Matthew D. Hickey, David J. Quan, Peter V. Chin‐Hong, John P. Roberts – 22 March 2013 – Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from the American Thoracic Society recommend treatment for latent tuberculosis in this population.
Neta Barashi, Ido D. Weiss, Ori Wald, Hanna Wald, Katia Beider, Michal Abraham, Shiri Klein, Daniel Goldenberg, Jonathan Axelrod, Eli Pikarsky, Rinat Abramovitch, Evelyne Zeira, Eithan Galun, Amnon Peled – 21 March 2013 – Human hepatocellular carcinoma (HCC) is an inflammation‐induced cancer, which is the third‐leading cause of cancer mortality worldwide. We investigated the role of the chemokine receptors, CCR5 and CCR1, in regulating inflammation and tumorigenesis in an inflammation‐induced HCC model in mice.
Frank Tacke, Hiroyuki Yoneyama – 20 March 2013
Joachim Lupberger, François H.T. Duong, Isabel Fofana, Laetitia Zona, Fei Xiao, Christine Thumann, Sarah C. Durand, Patrick Pessaux, Mirjam B. Zeisel, Markus H. Heim, Thomas F. Baumert – 20 March 2013 – Interferon‐alpha (IFN‐α) exhibits its antiviral activity through signal transducer and activator of transcription protein (STAT) signaling and the expression of IFN response genes (IRGs). Viral infection has been shown to result in activation of epidermal growth factor receptor (EGFR)—a host cell entry factor used by several viruses, including hepatitis C virus.